BIRB-1017

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameBIRB-1017
Drug Alias NameBIRB-1017
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 mitogen-activated protein kinase inhibitorsTumor necrosis factor α inhibitors
TargetsP38 mitogen-activated protein kinaseTumor necrosis factor α
Therapy Area/IndicationsPsoriasisArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Clinical)
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. Kg
Active IndicationsN/A
Inactive IndicationsPsoriasisArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A